CSL to Separate Vaccine Business, Cut Jobs

CSL Behring parent company to lay off 15% of its global workforce, close 2 area plasma centers

CSL to separate vaccine business, cut jobs

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” and “highly irrational.”

Biotech giant CSL to cut 3000 jobs, spin off flu arm

Biotech giant CSL is set to axe almost 3000 jobs globally as part of a major restructure that will see its flu vaccine arm spun off into a separately listed company and slash costs.

CSL to Cut 4,800 Jobs, Spin Off Vaccine Unit

Australian biotech giant CSL has announced a sweeping restructure that will see around 4,800 jobs cut, equal to 15 percent of its workforce, as part of efforts to streamline operations. The company will also shut 22 underperforming plasma centres in the 2026 financial year. CEO Paul McKenzie said the overhaul would deliver annual cost savings of $550 million over three years, though it would involve one-off restructuring costs of between $700 mi…

CSL to cut almost 3000 jobs, spin off vaccines unit in major restructure

Global biotech firm plans a major overhaul, including sweeping cost cuts, to ward off growing pressure on earnings.

CSL to Spin Off Vaccine Unit Seqirus, Plans $487 Million Buyback

Australian biotech giant CSL Ltd. said it will spin off its Seqirus vaccine business into a separately listed company, as it reported full-year profit that was slightly higher than expected.